We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Read MoreHide Full Article
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) is well-poised for growth on the back of a broad range of dialysis products and services and a solid global foothold. However, stiff competition remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 32.3% year to date against the industry’s decline of 6.5%. The S&P 500 Index has gained 14.2% in the same time frame.
The company, with a market capitalization of $11.51 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 24.4% in 2024 after declining in 2023. FMS’ earnings beat estimates in three of the trailing four quarters and missed the same once, delivering an average surprise of 43.17%.
Image Source: Zacks Investment Research
Key Catalysts
Fresenius Medical provides a wide range of dialysis products in its dialysis and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.
The company offers an extensive array of Hemodyalisis, Peritoneal dialysis and Acute Dialysis products. It is focused on further expanding its home dialysis offerings in order to further boost the quality of life for patients and increase their choice of available treatments.
In August, FMS received 510(k) clearance from the FDA for Versi HD with GuideMe Software — the next-generation portable automated peritoneal dialysis system with a completely reinvented self-guided interface. The software can facilitate a smooth and safe switch from hospital to home with easier training experiences. The company has planned to launch the VersiHD with GuideMe Software in selected markets in 2023. Moreover, existing users of VersiHD are also eligible for an upgrade to the GuideMe Software.
Fresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), the Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches like enhancing its organic growth and making strategic and suitable acquisitions. It also aims to align its business activities through public-private partnerships in the dialysis business to tap into new markets in the coming quarters.
Although FMS exited the third quarter on a dismal note, its results reflected strong organic growth on the back of improving treatment volumes as well as a stabilizing labor environment in the United States. A potential continuation of improvement in these two key factors will be beneficial for the company in the rest of 2023. Overall price improvements also supported growth in the Care Enablement segment.
Meanwhile, FMS’ newly implemented operating model led to operational improvements. The bottom line was hurt by inflationary cost increases in energy, material and personnel. These headwinds are likely to improve going forward, which also reflected in the company’s operating outlook.
What’s Hurting the Stock?
Fresenius Medical has numerous competitors in the field of health care services and the sale of dialysis products. Intense competition in the niche markets is likely to hamper the company’s sales opportunities, which, in turn, can lead to a loss of market share.
Recently, positive data from a late-stage study evaluating Novo Nordisk’s new diabetes drug, Ozempic, has raised concern about a potential rise in competitionfor Fresenius Medical. Clinical data suggests that the adoption of Ozempic may have an adverse impact on the dialysis of patients — a major source of FMS’ revenues — going forward.
A lower volume of dialysis led by a potential delay in chronic kidney disease (due to the use of Ozempic) can be detrimental for Fresenius Medical’s top line. Shares of the company plunged significantly following the announcement of the Ozempic study data last week.
U.S. revenues continued to be hurt by the FX impact. Moreover, the bottom line was hurt by inflationary cost increases in energy, material and personnel. However, FMS’ cost-saving initiatives have helped cushion the decline in operating margin. Meanwhile, planned divestitures, as part of the company’s transformational plan, will lead to a loss of revenues going forward.
Estimate Trend
The Zacks Consensus Estimate for 2023 revenues is pegged at $21.16 billion, indicating growth of 3.7% from the previous year’s reported number. The consensus mark for earnings is pinned at $1.27 per share, implying a decline of 22.6% from the year-ago level.
Cardinal Health has an estimated long-term growth rate of 15.2%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.67%.
CAH’s shares have rallied 35.4% year to date.
Biodesix has an estimated growth rate of 22.7% for 2024. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 9.76%.
BDSX’s shares have lost 44.8% year to date.
Patterson Companies has an estimated long-term growth rate of 9.2%. PDCO’s earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 8.47%.
PDCO’s shares have risen 8.8% year to date.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) is well-poised for growth on the back of a broad range of dialysis products and services and a solid global foothold. However, stiff competition remains a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 32.3% year to date against the industry’s decline of 6.5%. The S&P 500 Index has gained 14.2% in the same time frame.
The company, with a market capitalization of $11.51 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 24.4% in 2024 after declining in 2023. FMS’ earnings beat estimates in three of the trailing four quarters and missed the same once, delivering an average surprise of 43.17%.
Image Source: Zacks Investment Research
Key Catalysts
Fresenius Medical provides a wide range of dialysis products in its dialysis and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.
The company offers an extensive array of Hemodyalisis, Peritoneal dialysis and Acute Dialysis products. It is focused on further expanding its home dialysis offerings in order to further boost the quality of life for patients and increase their choice of available treatments.
In August, FMS received 510(k) clearance from the FDA for Versi HD with GuideMe Software — the next-generation portable automated peritoneal dialysis system with a completely reinvented self-guided interface. The software can facilitate a smooth and safe switch from hospital to home with easier training experiences. The company has planned to launch the VersiHD with GuideMe Software in selected markets in 2023. Moreover, existing users of VersiHD are also eligible for an upgrade to the GuideMe Software.
Fresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), the Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches like enhancing its organic growth and making strategic and suitable acquisitions. It also aims to align its business activities through public-private partnerships in the dialysis business to tap into new markets in the coming quarters.
Although FMS exited the third quarter on a dismal note, its results reflected strong organic growth on the back of improving treatment volumes as well as a stabilizing labor environment in the United States. A potential continuation of improvement in these two key factors will be beneficial for the company in the rest of 2023. Overall price improvements also supported growth in the Care Enablement segment.
Meanwhile, FMS’ newly implemented operating model led to operational improvements. The bottom line was hurt by inflationary cost increases in energy, material and personnel. These headwinds are likely to improve going forward, which also reflected in the company’s operating outlook.
What’s Hurting the Stock?
Fresenius Medical has numerous competitors in the field of health care services and the sale of dialysis products. Intense competition in the niche markets is likely to hamper the company’s sales opportunities, which, in turn, can lead to a loss of market share.
Recently, positive data from a late-stage study evaluating Novo Nordisk’s new diabetes drug, Ozempic, has raised concern about a potential rise in competitionfor Fresenius Medical. Clinical data suggests that the adoption of Ozempic may have an adverse impact on the dialysis of patients — a major source of FMS’ revenues — going forward.
A lower volume of dialysis led by a potential delay in chronic kidney disease (due to the use of Ozempic) can be detrimental for Fresenius Medical’s top line. Shares of the company plunged significantly following the announcement of the Ozempic study data last week.
U.S. revenues continued to be hurt by the FX impact. Moreover, the bottom line was hurt by inflationary cost increases in energy, material and personnel. However, FMS’ cost-saving initiatives have helped cushion the decline in operating margin. Meanwhile, planned divestitures, as part of the company’s transformational plan, will lead to a loss of revenues going forward.
Estimate Trend
The Zacks Consensus Estimate for 2023 revenues is pegged at $21.16 billion, indicating growth of 3.7% from the previous year’s reported number. The consensus mark for earnings is pinned at $1.27 per share, implying a decline of 22.6% from the year-ago level.
Fresenius Medical Care AG & Co. KGaA Price
Fresenius Medical Care AG & Co. KGaA price | Fresenius Medical Care AG & Co. KGaA Quote
Stocks to Consider
Some better-ranked stocks from the same medical industry are Cardinal Health (CAH - Free Report) , Biodesix (BDSX - Free Report) and Patterson Companies (PDCO - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health has an estimated long-term growth rate of 15.2%. Its earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 15.67%.
CAH’s shares have rallied 35.4% year to date.
Biodesix has an estimated growth rate of 22.7% for 2024. Its earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 9.76%.
BDSX’s shares have lost 44.8% year to date.
Patterson Companies has an estimated long-term growth rate of 9.2%. PDCO’s earnings surpassed estimates in three of the trailing four quarters and met the same once, delivering an average surprise of 8.47%.
PDCO’s shares have risen 8.8% year to date.